Apollo Endosurgery Inc (APEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH61236D
- Pages: 46
- November 2018
- Total Views:1157
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Apollo Endosurgery Inc (Apollo Endo), formerly Lpath Inc, is a medical technology company that designs, develops and commercializes medical devices used for the treatment of obesity. The company's product portfolio comprises endo-bariatric products such as Orbera Intragastric Balloon System and OverStitch endoscopic suturing system; and Lap-Band system for laparoscopic bariatric surgeries. These surgical and non-surgical interventional devices are also used in procedures that address or repair a variety of gastrointestinal defects. Apollo Endo's products are used by bariatric surgeons, general surgeons and gastroenterologists. It has a manufacturing facility in the Coyol Free Trade Zone in Alajuela, Costa Rica. Apollo Endo is headquartered in Austin, Texas, the US.
Apollo Endosurgery Inc (APEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Apollo Endosurgery Inc, Medical Devices Deals, 2012 to YTD 2018 9
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To USD 110 Million 11
Merger 13
Lpath and Apollo Endosurgery Merges 13
Equity Offering 14
Apollo Endosurgery Raises USD23.7 Million in Public Offering of Shares 14
Apollo Endosurgery to Raise up to USD16 Million in Public Offering of Shares 15
Apollo Endosurgery Raises USD36 Million in Public Offering of Shares 16
Lpath Raises USD12.5 Million in Private Placement of Shares 18
Lpath Files Registration Statement For Public Offering Of Class A Common Stock For Up To USD 20 Million 20
Lpath Files Registration Statement For Public Offering Of Securities For Up To USD 40 Million 21
Lpath Completes Public Offering Of Shares For USD 12 Million 22
Lpath Announces Public Offering Of Class A Common Stock For USD 9.3 Million 23
Asset Transactions 24
Pfizer Plans To Sell Certain Ohthalmology R&D Assets 24
Apollo Endosurgery Inc-Key Competitors 25
Apollo Endosurgery Inc-Key Employees 26
Apollo Endosurgery Inc-Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 08, 2018: Apollo Endosurgery reports second quarter 2018 results 28
May 03, 2018: Apollo Endosurgery Reports First Quarter 2018 Results 30
Mar 01, 2018: Apollo Endosurgery Reports Fourth Quarter and Full Year 2017 Results 31
Oct 26, 2017: Apollo Endosurgery Reports Third Quarter 2017 Results 33
Aug 01, 2017: Apollo Endosurgery Reports Second Quarter 2017 Results 35
Jul 12, 2017: Apollo Endosurgery Reports Preliminary Unaudited Financial Estimates for the Second Quarter of 2017 37
May 04, 2017: Apollo Endosurgery Reports First Quarter 2017 Results 38
Mar 08, 2017: Apollo Endosurgery Reports Fourth Quarter and Full Year 2016 Results 39
Corporate Communications 41
May 31, 2018: Apollo Endosurgery Appoints Dr. Julie Shimer to Board of Directors 41
Nov 16, 2017: David C. Pacitti Joins Apollo Endosurgery Board of Directors 42
Jan 17, 2017: Apollo Endosurgery Appoints Dr. Christopher J. Gostout as Chief Medical Officer 43
Government and Public Interest 44
Jun 25, 2018: Two diabetes medications don't slow progression of type 2 diabetes in youth 44
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46
List Of Figure
List of Figures
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Apollo Endosurgery Inc, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apollo Endosurgery Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Apollo Endosurgery Inc, Medical Devices Deals, 2012 to YTD 2018 9
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To USD 110 Million 11
Lpath and Apollo Endosurgery Merges 13
Apollo Endosurgery Raises USD23.7 Million in Public Offering of Shares 14
Apollo Endosurgery to Raise up to USD16 Million in Public Offering of Shares 15
Apollo Endosurgery Raises USD36 Million in Public Offering of Shares 16
Lpath Raises USD12.5 Million in Private Placement of Shares 18
Lpath Files Registration Statement For Public Offering Of Class A Common Stock For Up To USD 20 Million 20
Lpath Files Registration Statement For Public Offering Of Securities For Up To USD 40 Million 21
Lpath Completes Public Offering Of Shares For USD 12 Million 22
Lpath Announces Public Offering Of Class A Common Stock For USD 9.3 Million 23
Pfizer Plans To Sell Certain Ohthalmology R&D Assets 24
Apollo Endosurgery Inc, Key Competitors 25
Apollo Endosurgery Inc, Key Employees 26
Apollo Endosurgery Inc, Other Locations 27
Apollo Endosurgery Inc, Subsidiaries 27
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Apollo Endosurgery Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Apollo Endosurgery Inc (Apollo Endo), formerly Lpath Inc, is a medical technology company that designs, develops and commercializes medical devices used for the treatment of obesity. The company's product portfolio comprises endo-bariatric products such as Orbera Intragastric Balloon System and OverStitch endoscopic suturing system; and Lap-Band system for laparoscopic bariatric surgeries. These surgical and non-surgical interventional devices are also used in procedures that address or repair a variety of gastrointestinal defects. Apollo Endo's products are used by bariatric surgeons, general surgeons and gastroenterologists. It has a manufacturing facility in the Coyol Free Trade Zone in Alajuela, Costa Rica. Apollo Endo is headquartered in Austin, Texas, the US.
Apollo Endosurgery Inc (APEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Apollo Endosurgery Inc, Medical Devices Deals, 2012 to YTD 2018 9
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To USD 110 Million 11
Merger 13
Lpath and Apollo Endosurgery Merges 13
Equity Offering 14
Apollo Endosurgery Raises USD23.7 Million in Public Offering of Shares 14
Apollo Endosurgery to Raise up to USD16 Million in Public Offering of Shares 15
Apollo Endosurgery Raises USD36 Million in Public Offering of Shares 16
Lpath Raises USD12.5 Million in Private Placement of Shares 18
Lpath Files Registration Statement For Public Offering Of Class A Common Stock For Up To USD 20 Million 20
Lpath Files Registration Statement For Public Offering Of Securities For Up To USD 40 Million 21
Lpath Completes Public Offering Of Shares For USD 12 Million 22
Lpath Announces Public Offering Of Class A Common Stock For USD 9.3 Million 23
Asset Transactions 24
Pfizer Plans To Sell Certain Ohthalmology R&D Assets 24
Apollo Endosurgery Inc-Key Competitors 25
Apollo Endosurgery Inc-Key Employees 26
Apollo Endosurgery Inc-Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 08, 2018: Apollo Endosurgery reports second quarter 2018 results 28
May 03, 2018: Apollo Endosurgery Reports First Quarter 2018 Results 30
Mar 01, 2018: Apollo Endosurgery Reports Fourth Quarter and Full Year 2017 Results 31
Oct 26, 2017: Apollo Endosurgery Reports Third Quarter 2017 Results 33
Aug 01, 2017: Apollo Endosurgery Reports Second Quarter 2017 Results 35
Jul 12, 2017: Apollo Endosurgery Reports Preliminary Unaudited Financial Estimates for the Second Quarter of 2017 37
May 04, 2017: Apollo Endosurgery Reports First Quarter 2017 Results 38
Mar 08, 2017: Apollo Endosurgery Reports Fourth Quarter and Full Year 2016 Results 39
Corporate Communications 41
May 31, 2018: Apollo Endosurgery Appoints Dr. Julie Shimer to Board of Directors 41
Nov 16, 2017: David C. Pacitti Joins Apollo Endosurgery Board of Directors 42
Jan 17, 2017: Apollo Endosurgery Appoints Dr. Christopher J. Gostout as Chief Medical Officer 43
Government and Public Interest 44
Jun 25, 2018: Two diabetes medications don't slow progression of type 2 diabetes in youth 44
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46
List Of Figure
List of Figures
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Apollo Endosurgery Inc, Medical Devices Deals, 2012 to YTD 2018 9
List Of Table
List of Tables
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Apollo Endosurgery Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Apollo Endosurgery Inc, Medical Devices Deals, 2012 to YTD 2018 9
Apollo Endosurgery Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Apollo Endosurgery Completes Acquisition Of Obesity Intervention Division Of Allergan For Up To USD 110 Million 11
Lpath and Apollo Endosurgery Merges 13
Apollo Endosurgery Raises USD23.7 Million in Public Offering of Shares 14
Apollo Endosurgery to Raise up to USD16 Million in Public Offering of Shares 15
Apollo Endosurgery Raises USD36 Million in Public Offering of Shares 16
Lpath Raises USD12.5 Million in Private Placement of Shares 18
Lpath Files Registration Statement For Public Offering Of Class A Common Stock For Up To USD 20 Million 20
Lpath Files Registration Statement For Public Offering Of Securities For Up To USD 40 Million 21
Lpath Completes Public Offering Of Shares For USD 12 Million 22
Lpath Announces Public Offering Of Class A Common Stock For USD 9.3 Million 23
Pfizer Plans To Sell Certain Ohthalmology R&D Assets 24
Apollo Endosurgery Inc, Key Competitors 25
Apollo Endosurgery Inc, Key Employees 26
Apollo Endosurgery Inc, Other Locations 27
Apollo Endosurgery Inc, Subsidiaries 27
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Apollo Endosurgery Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 179 | 
February 2020
Page 116 | January 2020
Page 235 | January 2020
Page 183 | September 2019
Page 244 | August 2019